A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorOno Pharmaceutical Co., Ltd.

About this trial

A study to investigate the safety, tolerability, and pharmacokinetics (PK) of ONO-6414 orally in healthy adult participants and in patients with active ulcerative colitis (UC).

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Male or female, age ≥18- to ≤55-year-old at the time of signing ICF.

Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, 12-lead ECG, vital signs measurements, and laboratory tests results, as evaluated by the investigator.

BMI of 18.0 to 32.0 kg/m2, inclusive, and a body weight of ≥50 kg at Screening.

Male or female, age ≥18-year-old at the time of signing ICF.

Disqualifiers

Mentally or legally incapacitated.

History or presence of clinically significant medical, surgical or psychiatric condition or disease that in the opinion of the investigator or medical monitor might confound the results of the study or pose an additional risk to the participant by their participation in the study, including but not limited to a history of inflammatory bowel disease, gastritis, ulcers, gastrointestinal or rectal bleeding; history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection or history or clinical evidence of pancreatic injury or pancreatitis, history of cardiac arrhythmia (both atrial and ventricular). History of uncomplicated appendectomy and uncomplicated cholecystectomy are allowed.

History of any major invasive surgery within 6 months before the first dosing, or minor invasive surgery within 7 days before the first dosing.

History of hypersensitivity or idiosyncratic reaction to the study interventions, excipients (including Lactose) or related compounds, or severe food allergies.

Trial design

Design model

Parallel

Treatments tested in this trial

  • ONO-6414

    Drug

    Administered orally

  • Placebo

    Drug

    Administered orally

Treatment groups

90 Participants
are divided into 3 treatment groups
Group A: ONO-6414: Single ascending doseExperimental treatment 2 interventions
Group B: ONO-6414: Multiple ascending doseExperimental treatment 2 interventions
Group C: ONO-6414: Single doseExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Safety and tolerability: Number of Participants with Adverse Events (AEs)

All parts

Time frame
Up to 168 hours post-dose
2

Pharmacokinetic parameter of ONO-6414: Cmax

All parts

Time frame
Predose and up to 72 hours post-dose
3

Pharmacokinetic parameter of ONO-6414: Tmax

All parts

Time frame
Predose and up to 72 hours post-dose
4

Pharmacokinetic parameter of ONO-6414: AUC

All parts

Time frame
Predose and up to 72 hours post-dose

Secondary outcomes

1

Effect of food on Cmax of ONO-6414

SAD part

Time frame
Predose and up to 72 hours post-dose
2

Effect of food on AUClast of ONO-6414

SAD part

Time frame
Predose and up to 72 hours post-dose

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.